ten23 health involved in development of innovative therapy
The American pharmaceutical company scPharmaceuticals has obtained a US regulatory approval for its innovative treatment FUROSCIX®. The Valais region played a key role in this: ten23 health and its subsidiary Swissfillon in Visp provided decisive support to scPharmaceuticals in this development.
"We are very pleased to have supported scPharmaceuticals in the development of FUROSCIX®, which is scheduled to be launched in the first quarter of 2023. With our unique know-how and experience in filling complex sterile pharmaceuticals, such as the 10 ml polymer cartridge, used in the body infuser for FUROSCIX, we offer complete solutions to our partners," said Professor Hanns-Christian Mahler, CEO of ten23 health.
What is special about the new therapy?
FUROSCIX® can be administered subcutaneously at home by the patient or a caregiver using the body infusion set for FUROSCIX®. The pre-filled cartridge is inserted into the disposable infuser, attached to the abdomen, and activated by a button to deliver the dose over five hours. The FUROSCIX® infuser delivers a single 80 mg dose.
Source: ten23 health press release